From Our 2012 Archives
Drugs Hold Promise for Severe Juvenile Arthritis Patients
Latest Arthritis News
Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs -- canakinumab and tocilizumab -- reduce symptoms, including severe joint pain experienced by children with systemic juvenile idiopathic arthritis (JIA).
"Systemic juvenile idiopathic arthritis is a form of severe arthritis which until a few years ago was treated mainly with corticosteroids which have known side effects, especially growth impairment," said Dr. Nicolino Ruperto, a pediatric rheumatologist at G. Gaslini Children's Hospital in Genoa and co-author of the studies. The research looked at the safety and effectiveness of the interleukin-1 inhibitor canakinumab and the interleukin-6 inhibitor tocilizumab.
The disease is one of seven types of juvenile idiopathic arthritis that affect one in 1,000, or roughly 294,000, children in the United States, according to the U.S. National Institutes of Health. It is characterized by inflammation of one or more joints, fever and rash, among other health problems. "Idiopathic" means the cause is unknown.
In the canakinumab study, funded by drug maker Novartis Pharma, two trials took place. In one, patients received the drug subcutaneously (injected just below the skin) or a placebo. In the other, canakinumab was taken knowingly, or open-label.
"The study demonstrated that among 190 children with systemic JIA, about 60 percent of the children treated for several months had a complete disappearance of both arthritis, fever and rash," said Ruperto. One-third also discontinued corticosteroids, he said.
Ruperto said canakinumab works by reducing the level of a cytokine (a protein)called interleukin-1 that leads to the inflammation -- the arthritis and fever -- in children with systemic juvenile idiopathic arthritis.
In the study of tocilizumab, researchers from the Ospedale Pediatrico Bambino Gesu, a children's hospital in Rome, randomly assigned 112 children, aged 2 to 17, with systemic juvenile idiopathic arthritis to one of two doses given intravenously or a placebo every two weeks for three months. Patients who did not respond were offered the drug open label after that and followed for about a year. At 12 weeks, 71 percent who received tocilizumab had no fever and improved pain compared to 8 percent in the placebo group. This study was funded by drug maker Hoffmann La Roche.
The research breaks new ground, said two Stanford University physicians, Dr. Christy Sandborg and Dr. Elizabeth Mellins, who wrote an accompanying journal editorial. "There is no doubt that the agents tested in these trials signal a new era in the treatment of systemic JIA and will shed light on the mechanisms driving this enigmatic disorder," they wrote.
But they also said important questions remain about the drugs' side effects, and they noted that some children in the trials experienced macrophage activation syndrome, a serious, systemwide inflammation that is a complication of JIA that could also be related to the interleukin drugs.
Dr. Patience White, vice president for public health at the Arthritis Foundation and a professor of pediatrics and medicine at George Washington University School of Medicine and Health Sciences, said, "These trials are very exciting because the response rates are much better than responses to other biologic drug trials to date."
Still, concerns exist. "While it is exciting work, from a parent point of view, it can be an anxiety-provoking decision to decide to start their child on a new drug for which the full side-effect profile is not known," she said.
She said neither drug has a long track record in treating this condition, and unknown side effects don't always arise in early drug trials. Mass-market use sometimes reveals additional pros and cons of a medication.
She said families interested in trying the interleukin drugs should first see a physician who specializes in juvenile rheumatology. "See someone who knows about these drugs, and make sure your child is part of a registry so that everybody learns from the experience with it," she said.
Currently, only tocilizumab is approved to treat systemic juvenile idiopathic arthritis, said Ruperto. For canakinumab, the evaluation process is ongoing in the United States and Europe. If it's approved, he said, "It is likely that insurance companies will have to pay for it."
"Before this," said White, "we really haven't had drugs that really made that much difference whereas these clearly do... The beauty of these trials is that they're opening up opportunity to see the results of targeting new steps in the inflammatory process."
Copyright © 2012 HealthDay. All rights reserved.
SOURCES: Nicolino Ruperto, M.D., MPH, Istituto G. Gaslini, Di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Gaslini, Genoa, Italy; Patience White, M.D., vice president for public health, Arthritis Foundation, and professor of pediatrics and medicine at George Washington University School of Medicine and Health Sciences, Washington, D.C.; Dec. 19, 2012New England Journal of Medicine